FX1
|
|
|
- CAS-Nr.
- 1426138-42-2
- Englisch Name:
- FX1
- Synonyma:
- FX1;CS-2497;FX-1;FX 1;FX1（CS-2497）;FX1 >=98% (HPLC);inhibit,Apoptosis,Bcl-2 Family,FX 1,FX1,FX-1,Inhibitor;(Z)-3-(5-(5-chloro-2-oxoindolin-3-ylidene)-4-oxo-2-thioxothiazolidin-3-yl)propanoic acid;(5Z)-5-(5-Chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)-4-oxo-2-thioxo-3-thiazolidinepropanoic acid;3-Thiazolidinepropanoic acid, 5-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)-4-oxo-2-thioxo-, (5Z)-;3-{5-[(3Z)-5-chloro-2-oxo-2,3-dihydro-1H-indol-3-ylidene]-4-oxo-2-thioxo-1,3-thiazol-3-yl}propanoic acid
- CBNumber:
- CB03312337
- Summenformel:
- C14H9ClN2O4S2
- Molgewicht:
- 368.82
- MOL-Datei:
- 1426138-42-2.mol
|
FX1 Eigenschaften
- storage temp.
- 2-8°C
- L?slichkeit
- DMSO:24.22(Max Conc. mg/mL);65.67(Max Conc. mM)
DMF:30.0(Max Conc. mg/mL);81.34(Max Conc. mM)
- Aggregatzustand
- powder
- Farbe
- white to beige
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitssch?dlich bei Verschlucken. |
Akute Toxizit?t oral |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
|
| Sicherheit |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach M?glichkeit entfernen. Weiter spülen. |
|
FX1 Chemische Eigenschaften,Einsatz,Produktion Methoden
Verwenden
(5Z)-5-(5-Chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)-4-oxo-2-thioxo-3-thiazolidinepropanoic Acid is used in the preparation of substituted isatinylidenerhodanines. BCL6 inhibitor, an anticancer agent.
Biochem/physiol Actions
FX1 is a BCL6 inhibitor that effectively blocks BCL6 N-terminal BTB domain-mediated corepressors chromosome recruitment (by 61-87%/SMRT and 67-82%/BCOR; 50 μM FX1 for 30 min) and selectively suppresses BCL6-depenent growth (GI50 16-54 μM; >125 μM against BCL6-independent cells) in diffuse large B cell lymphoma (DLBCL) cultures, exhibiting greater affinity than its structure analog 79-6 or BCL6 corepressor SMRT for BTB domain (KD = 7 μM/FX1, 30 μM/SMRT, 129 μM/79-6). FX1 shows greater efficacy than 79-6 in reversing BCL6/corepressors-mediated target genes repression in vitro (IC50 = 35 μM vs. 318 μM with 79-6 by HEK293T-based reporter assay) and in suppressing OCI-Ly7 DLBCL xenograft tumor growth mice in vivo (100% vs. 45% suppression with respective compound via 25 mg/kg/day i.p.).
FX1 Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
FX1 Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 71)Lieferanten
- FX1
- FX-1;FX 1
- CS-2497
- (Z)-3-(5-(5-chloro-2-oxoindolin-3-ylidene)-4-oxo-2-thioxothiazolidin-3-yl)propanoic acid
- (5Z)-5-(5-Chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)-4-oxo-2-thioxo-3-thiazolidinepropanoic acid
- 3-Thiazolidinepropanoic acid, 5-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)-4-oxo-2-thioxo-, (5Z)-
- FX1 >=98% (HPLC)
- inhibit,Apoptosis,Bcl-2 Family,FX 1,FX1,FX-1,Inhibitor
- FX1（CS-2497）
- 3-{5-[(3Z)-5-chloro-2-oxo-2,3-dihydro-1H-indol-3-ylidene]-4-oxo-2-thioxo-1,3-thiazol-3-yl}propanoic acid
- 1426138-42-2
